Effect of COVID-19 on Breast Cancer Treatment Examined
MONDAY, May 3, 2021 -- More patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative breast cancer have been treated with neoadjuvant endocrine therapy (NET) due to COVID-19, according to a study presented at... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 3, 2021 Category: Pharmaceuticals Source Type: news
Fertility Concerns Impact Treatment Decisions in Breast Cancer
FRIDAY, April 30, 2021 -- Fertility concerns impact decision-making about endocrine therapy (ET) for some young women with breast cancer, according to a study published online April 22 in Cancer.
Tal Sella, M.D., from the Dana-Farber Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 30, 2021 Category: Pharmaceuticals Source Type: news
PET Predicts Response to Endocrine Therapy in ER+ Breast Cancer PET Predicts Response to Endocrine Therapy in ER+ Breast Cancer
Only half the women with ER+ breast cancer who get endocrine therapy respond. Could functional tests and a PET scan identify those women?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Effectiveness of endocrine therapy for breast cancer in men
(JAMA Network) This randomized clinical trial looked at changes in levels of the hormone estradiol in men with hormone receptor-positive breast cancer after three months of treatment with endocrine therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 4, 2021 Category: Cancer & Oncology Source Type: news
Entinostat Doesn't Overcome Endocrine Resistance in Breast Cancer Entinostat Doesn't Overcome Endocrine Resistance in Breast Cancer
The histone deacetylase inhibitor entinostat failed to overcome resistance to endocrine therapy in hormone receptor –positive, HER2-negative, advanced breast cancer in a phase 3 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
monarchE: Abemaciclib Reigns on in High-Risk Breast Cancer monarchE: Abemaciclib Reigns on in High-Risk Breast Cancer
Extended follow-up from monarchE shows ongoing event-free survival benefits with abemaciclib + endocrine therapy in high-risk early breast cancer, although even longer follow-up is required, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Postmenopausal women with early-stage BC/low recurrence score could skip adjuvant chemo
(American Association for Cancer Research) After a median follow-up of 5.1 years, among women with lymph node-positive early-stage breast cancer and a recurrence score of 25 or lower who received adjuvant endocrine therapy with or without chemotherapy, postmenopausal patients had no added benefit from chemotherapy, while premenopausal patients who received chemotherapy had improved invasive disease-free survival (IDFS) and an early indication of improved overall survival (OS), according to data from the SWOG S1007 RxPONDER clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2020 Category: Cancer & Oncology Source Type: news
High-risk, HR+, HER2-, early-stage BC patients continue to benefit from abemaciclib
(American Association for Cancer Research) Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented at the 2020 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2020 Category: Cancer & Oncology Source Type: news
Abemaciclib Beneficial for HR+, HER2 − Early Breast Cancer
TUESDAY, Oct. 6, 2020 -- For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), high-risk early breast cancer (EBC), the addition of abemaciclib to endocrine therapy (ET) increases the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2020 Category: Pharmaceuticals Source Type: news
Abemaciclib Beneficial for HR & #43;, HER2 & #8722; Early Breast Cancer
TUESDAY, Oct. 6, 2020 -- For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 −), high-risk early breast cancer (EBC), the addition of abemaciclib to endocrine therapy (ET) increases the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2020 Category: Pharmaceuticals Source Type: news
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients
This observational study of cancer patients diagnosed with Covid-19 (n=890; 218 in the UK) found no evidence that receipt of anti-cancer therapy (chemotherapy, targeted therapy, endocrine therapy and immunotherapy) was associated with mortality. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 10, 2020 Category: Consumer Health News Source Type: news
Novel Immune Activator Boosts Immunotherapy Benefit in TNBC Novel Immune Activator Boosts Immunotherapy Benefit in TNBC
The combination of a novel immune activator with pembrolizumab showed good activity, especially in women with disease that converted to triple negative after endocrine therapy.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 30, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news
' Eye-Opening': Cognitive Decline With Endocrine Tx for Breast Ca'Eye-Opening': Cognitive Decline With Endocrine Tx for Breast Ca
The loss of cognition that occurs with chemotherapy -- so called chemobrain -- also occurs when women with early breast cancer are treated with endocrine therapy alone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Adjuvant Chemoendocrine Therapy May Be Associated With Cognitive Impairment
Results from a subgroup of the TAILORx trial suggested that adjuvant chemoendocrine therapy is associated with significantly greater cancer-related cognitive impairment compared with endocrine therapy alone. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
' Encouraging' Results With Pre-Op Therapy for DCIS'Encouraging' Results With Pre-Op Therapy for DCIS
There ' s a template now for treating DCIS with pre-operative endocrine therapy, and it shows that 15% of patients have a pathologic complete response.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 17, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
